• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

Bil­lion­aire-backed TCR start­up scores its first mar­quee in­dus­try al­liance

3 years ago
R&D

No­var­tis of­floads neu­rode­vel­op­men­tal dis­or­der as­set to small Swiss biotech

3 years ago
Startups
Deals

Qi­a­gen picks up DNA foren­sics com­pa­ny for $150M

3 years ago
Deals
Diagnostics

#JPM23 kicks off with an ac­qui­si­tion as Chiesi inks all-cash $1B+ deal for Am­ryt

3 years ago
Deals
Pharma

Un­pack­ing FDA’s lat­est Alzheimer’s OK; A look at all drugs ap­proved in 2022; Mod­er­na’s deal spree; Pfiz­er ...

3 years ago
Weekly

Doc­tors in­clined to pre­scribe new Alzheimer’s drug de­spite con­cerns

3 years ago
R&D

Emer­gent award­ed $379M+ to sup­ply the DOD with a skin de­con­t­a­m­i­na­tion lo­tion

3 years ago
Deals
Pharma

Pre­ci­sion Bio­Sciences gets pos­i­tive CMC feed­back for al­lo­gene­ic CAR-T can­di­date

3 years ago
FDA+
Manufacturing

Ei­sai prices Alzheimer's drug at $26,500, be­low part­ner Bio­gen's Aduhelm

3 years ago
Pharma
FDA+

BioN­Tech inks part­ner­ship with UK to speed up re­cruit­ment of mR­NA can­cer tri­als

3 years ago
Pharma

FDA grants pri­or­i­ty re­views for Pfiz­er's Pre­vnar 20 for kids and Roche lym­phoma can­di­date

3 years ago
Pharma
FDA+

Break­ing: FDA clears sec­ond Alzheimer's drug in 'foun­da­tion­al spark' for field

3 years ago
R&D
Pharma

Brands in de­mand: Keytru­da, Dupix­ent and Ozem­pic lead 2023 new sales pre­dic­tions — Eval­u­ate re­port

3 years ago
Pharma
Marketing

Amolyt hauls in €130M round to fund PhI­II tri­al of hy­poparathy­roidism drug

3 years ago
Financing

Three biotechs start the year with job cuts; Re­gen­eron ex­pands deal with blue­bird spin­out 

3 years ago
News Briefing

Tu­mor gene ther­a­py de­vel­op­er re­brands, emerges with $30M from blue-chip in­vestors

3 years ago
Financing

GSK, Cure­Vac forge ahead with mid-stage plans for flu, Covid mR­NA vac­cines

3 years ago
R&D

Bet­ting on cell mem­o­ry, Ab­b­Vie pays Im­munome $30M up­front to fur­ther an­ti­body re­search

3 years ago
Deals

Six years lat­er, SEC drops claims of ac­count­ing fraud against biotech ex­ec

3 years ago
People
Law

An an­tibi­otics biotech be­gins wind-down, lays off near­ly all work­ers

3 years ago
People
R&D

Syn­thekine nabs $100M to boost IL-2 pro­grams af­ter ri­vals hit set­backs

3 years ago
Financing
Startups

Up­dat­ed: Sick­le cell gene edit­ing start­up halts tri­al af­ter flag­ging se­ri­ous side ef­fect in first pa­tient

3 years ago
R&D
Cell/Gene Tx

Bio­gen names de­vel­op­ment chief as it braces for lecanemab de­ci­sion; Zymeworks CMO is shown the door

3 years ago
Peer Review

Pfiz­er tags ear­ly re­search pro­grams for 'ex­ter­nal­iza­tion' as it nar­rows fo­cus in rare dis­ease, can­cer

3 years ago
R&D
First page Previous page 394395396397398399400 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times
Endpoints News

Log in to your account

email

password

Endpoints News

request login link

Enter the email associated to with your Endpoints account, and we'll send you a one-time login link (no password needed). The link expires after 24 hours.

email

Endpoints News

reset password

Enter the email associated to with your Endpoints account, and we'll send you a link to reset your password. The link expires after 24 hours and can only be used once.

email

Endpoints News

Sign up for free to read a limited number of articles each month.

About You

Newsletter Interests

Pick what newsletters get delivered to your inbox each week.

Biopharma

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 3:30 PM ET

BREAKING NEWS ALERTS 2-3 times a week

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET

POST-HOC 1-2 times a week

Healthcare

ENDPOINTS HEALTH TECH Tuesday, Thursday at 10 AM ET

BREAKING NEWS ALERTS 2-3 times a week

Want unlimited access? Sign up for a premium subscription plan.